Outlook Therapeutics, Inc. , a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
Outlook Therapeutics stock last closed at $1.47, up 1.38% from the previous day, and has decreased 81.83% in one year. It has underperformed other stocks in the Biotechnology industry by 0.04 percentage points. Outlook Therapeutics stock is currently +68.97% from its 52-week low of $0.87, and -84.18% from its 52-week high of $9.29.
As of Apr 21, 2025, there are 32.02M OTLK shares outstanding. The market value of OTLK is $47.07M. In the last 24 hours, 225,778 OTLK shares were traded.
How to Buy Outlook Therapeutics Stock
Not sure how to invest in Outlook Therapeutics stock? Here's how.
Decide where to buy Outlook Therapeutics stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you choose where to buy Outlook Therapeutics stock.
Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
Deposit money your investment account: Pick your method of payment and add your information.
Research Outlook Therapeutics stock: The Outlook Therapeutics ticker symbol is OTLK. Is Outlook Therapeutics stock a good investment? Should you buy shares of OTLK? How do OTLK's underlying business fundamentals look? Do top analysts think Outlook Therapeutics is a good buy? Why has OTLK's stock price moved recently? (Hint: Our stock market analysis website can help you decide if OTLK is a good stock to buy).
Place your OTLK buy order: Decide if you will purchase OTLK shares at the current market price or use a limit order to buy OTLK stock at a specific price.
Get key alerts regarding your OTLK position: Create a watchlist to get live updates on your new investment in Outlook Therapeutics stock.
Step 1: Decide where to buy Outlook Therapeutics stock
You will need an online brokerage account in order to access the NASDAQ market and buy OTLK shares.
A brokerage account is an investment account that enables you to buy and sell a number of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
Based on our research, eToro is the best online stock brokerage. Here's why:
Invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
Access to world markets: From Technology to Financial Services, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
Social investing: eToro boasts a community of more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by creating an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open your brokerage account
Now that you've chosen your brokerage, it's time to fill out some personal info so you can invest in OTLK stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Outlook Therapeutics stock
Once you have chosen the best place to buy Outlook Therapeutics stock, it's important to analyze their stock before you buy, so you actually wrap your head around the risk as well as the upside.
Overview of key OTLK info
OTLK Price
$1.47
1w %
5.76%
1y %
-81.83%
5y %
-89.18%
P/E
-0.32x
P/B
-0.94x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$46.81M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$47.07M
Next Earnings
May 14, 2025
Next Dividend
N/A
Outlook Therapeutics Fundamentals
WallStreetZen was created to help part-time investors perform more in-depth fundamental analysis quickly.
Last year, OTLK revenue was $0.00. In the past 5 year, OTLK's revenue has gone up by -100% per year. This was slower than the Biotechnology industry average of 44.31%.
No, Outlook Therapeutics doesn't provide an income stream by paying out dividends.
Get analysis from other investors
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Place your OTLK buy order
You have two main options:
Market order: A market order is an order to buy or sell a stock at the best available price. Market orders are usually sufficient.
Limit order: A limit order lets you buy or sell a security at a specific price (or better). If you want to be sure you're buying or selling at a given price, use a limit order.
Click the Open button and your broker will place your order.
If you want more assistance investing in stocks on eToro, watch the helpful video below:
How much does it cost to buy one Outlook Therapeutics share?
As of Apr 21, 2025, it costs $1.47 to buy one share of Outlook Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $0.74, you can buy 0.5 shares of OTLK.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.